Vaccine Adjuvants- FDA & CDC

The patient safety and efficacy of adjuvants are highly required as the vaccines are one of the lifesaving agents. Therefore, the FDA and CDC rules regarding the vaccine adjuvants are highly essential during vaccine formulation and manufacturing processes. CBER of FDA is responsible for vaccine regulation in the United States. Vaccine development process follows the same pathway as for drugs and other pharmaceutical agents. A sponsor must submit the Investigational New Drug application (IND) to FDA. The IND describes about the vaccine, quality control tests for release, and its method of manufacture. After the successful completion of all three phases of clinical development the Biologics License Application (BLA) are submitted. After getting the permission form FDA and CDC a vaccine may be marketed.

 

  • FDA Approved Vaccine Adjuvants
  • Factors Effecting Vaccine Preservation
  • Efficacy of Vaccines in Newborns
  • Pre-Formulation & Formulation Aspects
  • Vaccine Ingredients
  • Sudden Infant Death Syndrome (SIDS)
  • Vaccines During Pregnancy
  • Vaccine Safety Monitoring
  • Vaccine Injury Compensation Programme

Related Conference of Vaccine Adjuvants- FDA & CDC

July 27-28, 2018

31st Annual Congress on Vaccines & Clinical Trials

Vancouver, Canada
October 01-03, 2018

Vaccine R&D: International Vaccine Congress

Dubai, UAE
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan

Vaccine Adjuvants- FDA & CDC Conference Speakers

Recommended Sessions

Related Journals

Are you interested in